Search Results

You are looking at 91 - 100 of 889 items for :

  • "community" x
  • Refine by Access: All x
Clear All
Full access

Sharyn F. Worrall, Andrea J. Dwyer, Reese M. Garcia, Keavy E. McAbee, and Anjelica Q. Davis

, these unmet needs must be identified and prioritized within the CRC population. Although efforts to improve the patient and survivor experience have gained momentum over the past decade, it is essential to ensure that the CRC community has their needs

Full access

Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson, and Yi-Jen Chen

(OR, 1.68; 95% CI, 1.43–1.99; P <.001), Charlson-Deyo comorbidity score ≥2 (OR, 1.46; 95% CI, 1.18–1.81; P <.001), treatment at community facility rather than academic (OR, 1.27; 95% CI, 1.07–1.51; P =.006), and T2 disease compared with the

Full access

Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff

RCC in community practice were examined, focusing on systemic therapy. Patients and Methods Data Source and Study Sample NCI Patterns of Care Data: The NCI SEER program collects information on all cancer diagnoses in defined geographic

Full access

Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta

. Methods We identified 184 cases of primary adult HNSCC treated at an urban, community-based academic health center between March 1, 2005, and March 8, 2017. The study protocol was approved by the Institutional Review Board (IRB 2018-9739). Patients with

Full access

Judy Perotti, Elda Railey, Mary Lou Smith, and Cheya Pope

Full access

Rodger J. Winn

Full access

Peter R. Carroll and Andrew J. Vickers

Few clinical issues have polarized the oncology community as much as screening for prostate cancer, with advocates of prostate-specific antigen (PSA) testing vocal on one side and skeptics just as vocal on the other. At the NCCN 19th Annual Conference, Dr. Peter R. Carroll and Dr. Andrew J. Vickers tackled the controversy surrounding early detection of prostate cancer, focusing attention on the randomized trial results at the heart of the matter; over-detection (the Achilles’ heel of screening); and the rationale behind the new, streamlined 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection, which emphasize selective early detection and treatment and are tightly aligned with the NCCN Guidelines for Prostate Cancer.

Full access

William T. McGivney